<DOC>
	<DOCNO>NCT01496443</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetics safety TAK-875 , daily ( QD ) , without glimepiride participant type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>TAK-875 Glimepiride Drug-Interaction Study</brief_title>
	<detailed_description>TAK-875 develop Takeda Global Research Development , Inc. adjunct diet exercise improve glycemic control participant T2DM . This study determine whether administration glimepiride alters pharmacokinetics ( PK ) TAK-875 , whether TAK-875 affect PK glimepiride .</detailed_description>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . The participant male female T2DM newly diagnose , manage diet exercise alone , take 2 oral antidiabetic agent ( except insulin thiazolidinediones ( TZDs ) ) willing discontinue antidiabetic medication 2 week prior enrollment . 4 . The participant age 18 68 year , inclusive , time informed consent Day 1 . 5 . The participant weighs least 50 kg ( 110 lb ) body mass index ( BMI ) 18.0 40.0 kg/m2 , inclusive Screening . 6 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 30 day last dose . 7 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study 30 day last dose . 8 . The participant fasting serum glucose ( FPG ) &gt; 126 mg/dL &lt; 260 mg/dL diabetic medication , &lt; 220 mg/dL single antidiabetic agent , &lt; 200 mg/dL combination 2 oral antidiabetic agent Screening . 9 . The participant fasting Cpeptide concentration ≥0.8 ng/mL Screening . 10 . The participant receive treatment weightloss drug within 3 month prior Screening . 11 . The participant systolic blood pressure ≤160 mmHg diastolic blood pressure ≤100 mmHg Screening Checkin ( Day 1 ) . 12 . The participant meet one follow glycated hemoglobin ( HbA1c ) criterion ( diagnosis must base current American Diabetes Association ( ADA ) criterion ) Screening : Participant treatment naïve HbA1c concentration ≥6.5 % ≤10.0 % . Participant single antidiabetic agent ( stable dose least 28 day ) HbA1c ≥6 % ≤9.5 % . Participant combination 2 antidiabetic agent ( stable dos least 28 day ) HbA1c ≥6 % ≤9.0 % . 13 . The participant negative test result Screening Checkin ( Day 1 ) select substance abuse include alcohol cotinine . 14 . The participant Screening Checkin ( Day 1 ) clinical laboratory evaluation ( include fast clinical chemistry , hematology , complete urinalysis [ exclude glucose result ] ) within reference range test laboratory , unless investigator deems outofrange result clinically significant . 15 . The participant willing refrain strenuous exercise 72 hour Checkin ( Day 1 ) throughout study . 16 . The participant consider investigator good health ( diabetic ) determine medical history review , physical examination finding , electrocardiogram ( ECG ) vital sign result , clinical laboratory evaluation . 17 . The participant normal creatinine clearance &gt; 60 mL/min use CockcroftGault formula Screening Checkin ( Day 1 ) . 1 . The participant participate another investigational study take investigational drug within 30 day prior Checkin ( Day 1 ) . 2 . The participant receive TAK875 previous clinical study . 3 . The participant 's QTcF ( Fridericia 's correction ) &gt; 450 msec ( male female participant ) Screening Checkin ( Day 1 ) read printout ECG produce ECG equipment manually calculate evaluated investigator . 4 . The participant resting pulse heart rate &lt; 45 bpm &gt; 100 bpm Screening Checkin ( Day 1 ) . 5 . The participant immediate family member , study site employee , dependent relationship study site employee involve conduct study ( e.g. , spouse , parent , child , sibling ) may consent duress . 6 . The participant insulin TZD treatment . 7 . Participant know hypersensitivity component formulation TAK875 glimepiride ( see Package Insert ) . 8 . The participant positive urine drug result drug abuse Screening Checkin ( Day 1 ) . 9 . The participant history proteinuria &gt; 300 mg/day 12 24hour urine collection albumin/creatinine ratio &gt; 300 μg/mg Screening . If elevate , participant may rescreened within 1 week , may include study agreement Principal Investigator TGRD Medical Monitor . 10 . The participant history `` severe '' hypoglycemia ( defined Section 7.5.1 ) within 4 week prior Screening . 11 . The participant history clinically significant retinopathy , define moderate nonproliferative diabetic retinopathy stage proliferative diabetic retinopathy history lasertreated retinopathy . 12 . The participant history treat clinically significant peripheral autonomic neuropathy . 13 . The participant history ulcerative colitis Crohn 's disease , undergone gastric resection . 14 . The participant history psychiatric disorder affect participant 's ability participate study . 15 . The participant history angioedema . 16 . The participant acute , clinically significant illness within 30 day prior Checkin ( Day 1 ) , condition prior therapy , opinion investigator , would make participant unsuitable study . 17 . The participant history drug abuse ( define illicit drug use ) history alcohol abuse ( define regular daily consumption 4 alcoholic drink per day ) within 1 year prior Screening visit unwilling agree abstain alcohol drug throughout study . 18 . Participant take excluded medication , supplement food product . 19 . If female , participant pregnant lactate intend become pregnant , , within 30 day participate study ; intend donate ova time period . 20 . If male , participant intend donate sperm course study 30 day last dose study drug . 21 . The participant history cardiac arrhythmia , systolic dysfunction congestive heart failure , angina , myocardial ischemia infarction , stroke within 1 year prior Screening , presence abnormal ECG , investigator 's opinion , clinically significant . 22 . Participant current recent ( within 6 month ) gastrointestinal disease would expect influence absorption drug ( i.e. , history malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis , frequent [ per week ] occurrence heartburn , surgical intervention [ e.g. , cholecystectomy ] ) . 23 . The participant total bilirubin &gt; 1.5 mg/dL Screening Checkin ( Day 1 ) . 24 . Participant abnormal Screening Checkin ( Day 1 ) laboratory value suggest clinically significant underlying disease participant follow lab abnormality : ALT and/or Aspartate Aminotransferase ( AST ) level &gt; 2x ULN test laboratory , active liver disease , jaundice Screening Checkin ( Day 1 ) . 25 . The participant history abdominal surgery ( except laparoscopic cholecystectomy uncomplicated appendectomy ) , thoracic nonperipheral vascular surgery within 6 month prior Checkin ( Day 1 ) . 26 . Participant history cancer , basal cell Stage 1 squamous carcinoma skin remission least 5 year prior Day 1 . 27 . Participant positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) , know history human immunodeficiency virus infection Screening . 28 . Participant use nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 28 day prior Checkin ( Day 1 ) unwilling abstain product duration study positive cotinine test result Screening Checkin ( Day 1 ) . 29 . The participant poor peripheral venous access . 30 . The participant unwilling unable comply protocol schedule appointment . 31 . The participant unable understand verbal and/or write English language certify translation approve informed consent available . 32 . The participant donate blood experience acute blood loss ( include plasmapheresis ) &gt; 500 mL within 90 day prior Day 1 . 33 . Participant Screening Checkin ( Day 1 ) abnormal ( clinically significant ) ECG . Entry participant abnormal ( clinically significant ) ECG must approve , document signature principal investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>